FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

Inclusion Criteria:

• ECOG perfomance 0-1
• pathologically confirmed colorectal carcinoma, with RAS wild type
• inital unresectable liver metastases discussed by MDT
• prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery.
• without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)
• adequate blood, liver and renal function
• expected survival longer than 6 months

Exclusion Criteria:

• with bleeding risk
• interestinal obstruction or disease
• uncontrolled hypertension and severe heart disease
• previous severe thrombotic events
• central nervous system metastases
• accompanied with other malignant tumor